10.01.2011
- French drugmaker Sanofi-Aventis and Genzyme Corp are discussing options for significantly raising Sanofi's bid for the the U.S. biotech company to about $80 per share, the Wall...
07.01.2011
- Could it be time to talk in the long-running saga of Sanofi-Aventis $18.5 billion bid for Genzyme Corp? There is certainly the opportunity. The two chief executives at the center...
21.12.2010
- Genzyme argued that its experimental multiple sclerosis treatment will garner far higher sales than Sanofi-Aventis is projecting, as it aims to wrest a significantly higher bid...
14.12.2010
- Sanofi-Aventis named Elias Zerhouni as its new head of research and development as the French drugmaker reshapes its drug portfolio to offset sales losses from patent expiries...
13.12.2010
- Sanofi-Aventis has extended its snubbed $18.5 billion cash bid for U.S. biotech group Genzyme by six weeks, buying the French drugmaker time to persuade its reluctant target to...
06.12.2010
- Genzyme shareholder and board member Ralph Whitworth said the "ingredients are there" for a deal with Sanofi-Aventis , but the French drugmaker's $69-a-share offer is "not even a...
02.12.2010
- Sanofi-Aventis's CFO said a deal structure known as a contingent value right was interesting "in principle" but he declined to say if it was being discussed with bid target Genzyme...
30.11.2010
- Genzyme, resisting a hostile bid from Sanofi-Aventis, is open to a deal that links its value to the success of key drug Campath, the U.S. biotech's chief executive was quoted as...
